NCT02520375

Brief Summary

The aim of this study is to determine the impact of a prebiotic toothpaste and mouthrinse in periodontitis patients as an adjunct to scaling and rootplaning.

Trial Health

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 1, 2015

Completed
1 month until next milestone

First Posted

Study publicly available on registry

August 11, 2015

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2017

Completed
Last Updated

March 14, 2017

Status Verified

March 1, 2017

First QC Date

July 1, 2015

Last Update Submit

March 10, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • Pocket Probing Depth (PPD) at teeth with residual pockets

    Pocket probing depth measured with Merrit B prob

    Baseline - 6 months

Study Arms (2)

Prebiotic

EXPERIMENTAL

This group will be administered a prebiotic mouthrinse and toothpaste

Other: Prebiotic

Control

PLACEBO COMPARATOR

This group will be administered a control mouthrinse and toothpaste

Other: Control

Interventions

Prebiotic
ControlOTHER
Control

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • patients
  • ≥ 36 years of age
  • \- Page 4 of 4 \[DRAFT\] -
  • No previous scaling and rootplaning
  • Clinical diagnosis: severe generalized periodontitis characterized by the presence of \> 14 affected teeth when \> 14 teeth are present (if number of teeth present is \< 14, 8-14 teeth need to be affected) with an attachment loss of \> 6mm prior to initial non-surgical periodontal therapy.
  • A minimum of 3 natural teeth in every quadrant
  • Willing and able to give written informed consent

You may not qualify if:

  • Patients with aggressive periodontitis or necrotizing periodontitis
  • Patients who smoke
  • Pregnant or lactating woman
  • A history of diabetes, rheumatic fever, liver or kidney disease, neurological deficiencies, or use of medication which may affect periodontal tissue, (phenytoin, cyclosporin, nifedipine, chronic use of non-steroidal antiinflammatory drugs)
  • Patients with poorly controlled diabetes
  • Patients taking bisphosphonate mediation
  • Patient who have taken systemic antibiotics 3 months prior to treatment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Periodontitis

Interventions

Prebiotics

Condition Hierarchy (Ancestors)

Periodontal DiseasesMouth DiseasesStomatognathic Diseases

Intervention Hierarchy (Ancestors)

Dietary FiberDietary CarbohydratesCarbohydratesPolysaccharides, BacterialPolysaccharidesFoodDiet, Food, and NutritionPhysiological PhenomenaDietary SupplementsFood and Beverages
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 1, 2015

First Posted

August 11, 2015

Primary Completion

December 1, 2017

Last Updated

March 14, 2017

Record last verified: 2017-03